Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
8.55
-0.28 (-3.17%)
Apr 29, 2026, 10:52 AM EDT - Market open
Kura Oncology Revenue
In the year 2025, Kura Oncology had annual revenue of $67.48M with 25.24% growth. Kura Oncology had revenue of $17.34M in the quarter ending December 31, 2025, a decrease of -67.83%.
Revenue (ttm)
$67.48M
Revenue Growth
+25.24%
P/S Ratio
11.61
Revenue / Employee
$259,546
Employees
260
Market Cap
758.92M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ARS Pharmaceuticals | 84.28M |
| Arbutus Biopharma | 14.08M |
| Crescent Biopharma | 10.84M |
| Absci | 2.80M |
| Allogene Therapeutics | 22.00K |
KURA News
- 5 days ago - Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML - GlobeNewsWire
- 12 days ago - Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results - Benzinga
- 12 days ago - Kura Oncology Transcript: Investor Update - Transcripts
- 12 days ago - Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib - GlobeNewsWire
- 20 days ago - Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 - GlobeNewsWire
- 26 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Kura Oncology Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - Kura Oncology Transcript: Leerink Global Healthcare Conference 2026 - Transcripts